Diabetes mellitus and responsiveness of endometrial hyperplasia and early endometrial cancer to conservative treatment

References

• Kurman RJ, Carcangiu ML, Herrington CS, Young RH, editors. WHO classification of tumours of female reproductive organs. 4th ed. Lyon: IARC; 2014.
   Google Scholar
• Sanderson PA, Critchley HOD, Williams ARW, et al. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum Reprod Update. 2017;23:232–254.
   PubMed Web of Science ®Google Scholar
• Travaglino A, Raffone A, Saccone G, et al. Endometrial hyperplasia and risk of coexistent cancer: WHO vs EIN criteria. Histopathology. 2018;74:676–687.
   Web of Science ®Google Scholar
• Management of Endometrial Hyperplasia Green-top Guideline No. 67 RCOG/BSGE Joint Guideline | February 2016.
   Google Scholar
• Travaglino A, Raffone A, Saccone G, et al. PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2018;231:104–110.
   PubMed Web of Science ®Google Scholar
• Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016;27:16–41.
   PubMed Web of Science ®Google Scholar
• Gallos ID, Shehmar M, Thangaratinam S, et al. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2010;203:547.e.1–547.e.10.
   Web of Science ®Google Scholar
• Hashim HA, Ghaytay E, El Rakhawy M. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and meta-analysis of randomized trials. Am J Obstet Gynecol. 2015;213:469–478.
   PubMed Web of Science ®Google Scholar
• Yuk JS, Song JY, Lee JH, et al. Levonorgestrel-releasing intrauterine systems versus oral cyclic medroxyprogesterone acetate in endometrial hyperplasia therapy: a meta-analysis. Ann Surg Oncol. 2017;24:1322–1329.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Qi G, Kanis MJ, et al. Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia. Oncotarget. 2017;8:57642–57653.
   PubMedGoogle Scholar
• Giampaolino P, Di Spiezio Sardo A, Mollo A, et al. Hysteroscopic endometrial focal resection followed by levonorgestrel intrauterine device insertion as a fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial cancer: a retrospective study. J Minim Invasive Gynecol. 2018;26:648–656.
   PubMed Web of Science ®Google Scholar
• Koskas M, Uzan J, Luton D, et al. Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis. Fertil Steril. 2014;101:785–794.
   PubMed Web of Science ®Google Scholar
• Sato M, Arimoto T, Kawana K, et al. Measurement of endometrial thickness by transvaginal ultrasonography to predict pathological response to medroxyprogesterone acetate in patients with grade 1 endometrioid adenocarcinoma. Mol Clin Oncol. 2016;4:492–496.
   PubMed Web of Science ®Google Scholar
• Penner KR, Dorigo O, Aoyama C, et al. Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy. Gynecol Oncol. 2012;124:542–548.
   PubMed Web of Science ®Google Scholar
• Utsunomiya H, Suzuki T, Ito K, et al. The correlation between the response to progestogen treatment and the expression of progesterone receptor B and 17beta-hydroxysteroid dehydrogenase type 2 in human endometrialcarcinoma. Clin Endocrinol (Oxf). 2003;58:696–703.
   PubMed Web of Science ®Google Scholar
• Schrijnders D, Hendriks SH, Kleefstra N, et al. Sex differences in obesity related cancer incidence in relation to type 2 diabetes diagnosis (ZODIAC-49). PLoS One. 2018;13:e0190870.
   PubMed Web of Science ®Google Scholar
• Matsuo K, Ramzan AA, Gualtieri MR, et al. Prediction of concurrent endometrial carcinoma in women with endometrial hyperplasia. Gynecol Oncol. 2015;139:261–267.
   PubMed Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
   PubMed Web of Science ®Google Scholar
• Menke A, Casagrande S, Geiss L, et al. Prevalence of and trends in diabetes among adults in the United States, 1988-2012. JAMA. 2015;314:1021–1029.
   PubMed Web of Science ®Google Scholar
• Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors): development and validation of a newinstrument. ANZ J Surg. 2003;73:712–716.
   PubMed Web of Science ®Google Scholar
• Upson K, Allison KH, Reed SD, et al. Biomarkers of progestin therapy resistance and endometrial hyperplasia progression. Am J Obstet Gynecol. 2012;207:36.e1–36.e8.
   Web of Science ®Google Scholar
• Gallos ID, Ganesan R, Gupta JK. Prediction of regression and relapse of endometrial hyperplasia with conservative therapy. Obstet Gynecol. 2013;121:1165–1171.
   PubMed Web of Science ®Google Scholar
• Yang YF, Liao YY, Liu XL, et al. Prognostic factors of regression and relapse of complex atypical hyperplasia and well-differentiated endometrioid carcinoma with conservative treatment. Gynecol Oncol. 2015;139:419–423.
   PubMed Web of Science ®Google Scholar
• Chen M, Jin Y, Li Y, et al. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer. Int J Gynaecol Obstet. 2016;132:34–38.
   PubMed Web of Science ®Google Scholar
• Yang B, Xie L, Zhang H, et al. Insulin resistance and overweight prolonged fertility-sparing treatment duration in endometrial atypical hyperplasia patients. J Gynecol Oncol. 2018;29:e35.
   PubMed Web of Science ®Google Scholar
• Yang B, Xu Y, Zhu Q, et al. Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer. Gynecol Oncol. 2019;153:55–62.
   PubMed Web of Science ®Google Scholar
• Raglan O, Kalliala I, Markozannes G, et al. Risk factors for endometrial cancer: an umbrella review of the literature. Int J Cancer. 2018. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8:915–928.
   PubMed Web of Science ®Google Scholar
• Vitagliano G, Nosso G, Cotugno M, et al. One-year efficacy of liraglutide or bariatric surgery in obese type 2 diabetic patients: a retrospective study. G It Diabetol Metab. 2014;34:58–63.
   Google Scholar
• Wartko PD, Beck TL, Reed SD, et al. Association of endometrial hyperplasia and cancer with a history of gestational diabetes. Cancer Causes Control. 2017;28:819–828.
   PubMed Web of Science ®Google Scholar
• Fader AN, Arriba LN, Frasure HE, et al. Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol. 2009;114:121–127.
   PubMed Web of Science ®Google Scholar
• Yamamoto-Honda R, Takahashi Y, Yoshida Y, et al. Body mass index and the risk of cancer incidence in patients with type 2 diabetes in Japan: results from the National Center Diabetes Database. J Diabetes Investig. 2016;7:908–914.
   PubMedGoogle Scholar
• Sasaki LMP, Andrade KRC, Figueiredo A, et al. Factors associated with malignancy in hysteroscopically resected endometrial polyps: a systematic review and meta-analysis. J Minim Invasive Gynecol. 2018;25:777–785.
   PubMed Web of Science ®Google Scholar
• Chen YL, Cheng WF, Lin MC, et al. Concurrent endometrial carcinoma in patients with a curettage diagnosis of endometrial hyperplasia. J Formos Med Assoc. 2009;108:502–507.
   PubMed Web of Science ®Google Scholar
• Chen YL, Wang KL, Chen MY, et al. Risk factor analysis of coexisting endometrial carcinoma in patients with endometrial hyperplasia: a retrospective observational study of Taiwanese Gynecologic Oncology Group. J Gynecol Oncol. 2013;24:14–20.
   PubMed Web of Science ®Google Scholar
• Raffone A, Travaglino A, Saccone G, et al. Should progesterone and estrogens receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2019. [Epub ahead of print]
   Web of Science ®Google Scholar
• Bradley LD, Gueye NA. The medical management of abnormal uterine bleeding in reproductive-aged women. Am J Obstet Gynecol. 2016;214:31–44.
   PubMed Web of Science ®Google Scholar
• Raffone A, Travaglino A, Saccone G, et al. Management of women with atypical polypoid adenomyoma of the uterus: a quantitative systematic review. Acta Obstet Gynecol Scand. 2019. [Epub ahead of print]
   Web of Science ®Google Scholar
• Venturella R, Miele G, Cefalì K, et al. Subcutaneous progesterone for endometrial polyps in premenopausal women: a preliminary retrospective analysis. J Minim Invasive Gynecol. 2019;26:143–147.
   PubMed Web of Science ®Google Scholar
• Travaglino A, Raffone A, Saccone G, et al. Loss of B-cell lymphoma 2 immunohistochemical expression in endometrial hyperplasia: a specific marker of precancer and novel indication for treatment: a systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2018;97:1415–1426.
   PubMed Web of Science ®Google Scholar
• Raffone A, Travaglino A, Saccone G, et al. PAX2 in endometrial carcinogenesis and in differential diagnosis of endometrial hyperplasia. A systematic review and meta-analysis of diagnostic accuracy. Acta Obstet Gynecol Scand. 2018;98:287–299.
   Web of Science ®Google Scholar
• Raffone A, Travaglino A, Saccone G, et al. Loss of PTEN expression as diagnostic marker of endometrial precancer: a systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2018;98:275–286.
   Web of Science ®Google Scholar
• Travaglino A, Raffone A, Saccone G, et al. Immunohistochemical nuclear expression of β-catenin as a surrogate of CTNNB1 exon 3 mutation in endometrial cancer. Am J Clin Pathol. 2019;151:529–538.
   PubMed Web of Science ®Google Scholar
• Meireles CG, Pereira SA, Valadares LP, et al. Effects of metformin on endometrial cancer: systematic review and meta-analysis. Gynecol Oncol. 2017;147:167–180.
   PubMed Web of Science ®Google Scholar
• Clement NS, Oliver TR, Shiwani H, et al. Metformin for endometrial hyperplasia. Cochrane Database Syst Rev. 2017;10:CD012214.
   PubMedGoogle Scholar
• Mitsuhashi A, Uehara T, Hanawa S, et al. Prospective evaluation of abnormal glucose metabolism and insulin resistance in patients with atypical endometrial hyperplasia and endometrial cancer. Support Care Cancer. 2017;25:1495–1501.
   PubMed Web of Science ®Google Scholar